Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
27
×
Tags
national blog main
life sciences
biotech
boston blog main
national top stories
boston top stories
clinical trials
san francisco blog main
fda
boston
san francisco top stories
startups
deals
new york blog main
san diego blog main
san diego top stories
investing
new york top stories
cancer
detroit blog main
detroit top stories
raleigh-durham blog main
san francisco
seattle blog main
seattle top stories
texas blog main
texas top stories
boulder/denver blog main
boulder/denver top stories
bristol-myers squibb
drugs
europe blog main
gene therapy
indiana blog main
indiana top stories
ipo
medical device
national
raleigh-durham top stories
wisconsin blog main
What
therapeutics
27
×
drug
medicines
new
ipo
million
fda
treat
developing
medicine
raised
biotech
cancer
gene
phase
startup
therapy
ago
approval
approved
companies
company
crispr
data
disease
latest
momentum
nasdaq
rare
years
adding
based
bets
bio
biopharma
biotechs
black
chief
clinic
deal
Language
unset
Current search:
xconomy.com
×
photo
×
therapeutics
×
@xconomy.com
3 years ago
Dyne’s Upsized IPO Brings In $233M for Muscle Disorders Drug R&D
@xconomy.com
3 years ago
Biofourmis Hauls In $100M to Scale Digital Therapeutics Globally
@xconomy.com
3 years ago
Dyne Eyes IPO for R&D of Genetic Medicines for Rare Muscle Diseases
@xconomy.com
3 years ago
HotSpot Therapeutics Adds $65M to Steer Allosteric Medicines to the Clinic
@xconomy.com
4 years ago
Lyra Therapeutics IPO Raises $56M for Tests of Tech for Runny Noses
@xconomy.com
4 years ago
Esperion’s Combo Pill for Lowering Cholesterol Levels Wins FDA Nod
@xconomy.com
4 years ago
CRISPR, CAR-T, Consolidation: Top Advanced Therapy Milestones of 2019
@xconomy.com
4 years ago
Aimmune Awarded First FDA Approval for a Peanut Allergy Therapy
@xconomy.com
4 years ago
Bio Roundup: Mammoth Moves, Black Diamond’s Pop, Ohana’s Debut & More
@xconomy.com
4 years ago
Decibel Therapeutics Strikes a Balance, Adding Regenerative Med Focus
@xconomy.com
4 years ago
Black Diamond Lines Up IPO as Lead Cancer Drug Nears Clinic
@xconomy.com
4 years ago
Roche Puts Up Historic $1.15B for Sarepta Duchenne Gene Therapy Deal
@xconomy.com
4 years ago
Flagship’s Omega Aims to Take Epigenetic Drugs a Step Further
@xconomy.com
4 years ago
Frequency Plans IPO for Hearing Loss Drug & More Regenerative Meds
@xconomy.com
5 years ago
New Data Puts Aldeyra One Step Closer to FDA Filing for Eye Drug
@xconomy.com
5 years ago
In Landmark Gene-Editing Study, Sangamo Reports Little Benefit
@xconomy.com
5 years ago
Former Zavante Executive Tapped as Abide Therapeutics President
@xconomy.com
5 years ago
Sage Hits Mark in Postpartum Depression Phase 3 Trial, Stock Surges
@xconomy.com
5 years ago
To Boost Cancer Pipeline, Gilead Bets at Least $50M on Startup Tango
@xconomy.com
5 years ago
Delivery Robots in Big D, Rodriguez Leaves the Station, & More TX Tech
@xconomy.com
5 years ago
Qpex Biopharma Launches with $33M to Tackle Drug-Resistant Infections
@xconomy.com
5 years ago
TP Therapeutics Names New CEO, Gets $80M More For Cancer Drug Push
@xconomy.com
5 years ago
Bio Roundup: BIO Diversity, Allogene IPO, CRISPR In Utero & More
@xconomy.com
5 years ago
Sanofi Backs Click Therapeutics as Digital Medicines Gain Momentum
@xconomy.com
5 years ago
IPO Wave Rolls On as Five Life Science Firms Haul in $651M
@xconomy.com
5 years ago
Beam Therapeutics Spotlights CRISPR 2.0 with Precise Gene Editor, $87M
@xconomy.com
6 years ago
United Therapeutics Reaches $141M Deal for PAH Drug Firm SteadyMed